Beneficial effects of PPAR-γ ligands in ischemia-reperfusion injury, inflammation and shock

Cardiovascular Research

Volumn 65, Issue 4, 2005, Pages 772-781

  Abdelrahman, Maha ^a   Sivarajah, Ahila ^a   Thiemermann, Christoph ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Inflammation; Ischemia; PPAR ; Regional myocardial infarction; Reperfusion; Shock

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 15 DEOXY DELTA12,14 PROSTAGLANDIN J2; 15 HYDROXYICOSATETRAENOIC ACID; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CIGLITAZONE; GLITAZONE DERIVATIVE; INSULIN SENSITIZING AGENT; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROSTAGLANDIN A1; RETINOID X RECEPTOR; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; BONE EROSION; CYTOKINE PRODUCTION; DNA RESPONSIVE ELEMENT; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INFLAMMATION; INTESTINE INJURY; KIDNEY ISCHEMIA; LIPOGENESIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG INJURY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREATITIS; PRIORITY JOURNAL; PROMOTER REGION; REPERFUSION INJURY; REVIEW; SHOCK; SIGNAL TRANSDUCTION; STOMACH MUCOSA LESION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION; LIGANDS; MYOCARDIAL REPERFUSION INJURY; PPAR GAMMA; REPERFUSION INJURY; SHOCK;

EID: 13844297687     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2004.12.008     Document Type: Review

References (87)

1. R.M. Evans The steroid and thyroid hormone receptor superfamily Science 240 1988 889 895
2. D. Moras, and H. Gronemeyer The nuclear receptor ligand-binding domain: structure and function Curr. Opin. Cell Biol. 10 1998 384 391
3. M.E. Greene, B. Blumberg, O.W. McBride, H.F. Yi, K. Kronquist, and K. Kwan Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping Gene Expr. 4 1995 281 299
4. T. Sher, H.F. Yi, O.W. McBride, and F.J. Gonzalez cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor Biochemistry 32 1993 5598 5604
5. T. Yoshikawa, Z. Brkanac, B.R. Dupont, G.Q. Xing, R.J. Leach, and S.D. Detera-Wadleigh Assignment of the human nuclear hormone receptor, NUC1 (PPARD), to chromosome 6p21.1-p21.2 Genomics 35 1996 637 638
6. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 20 1999 649 688
7. O. Braissant, F. Foufelle, C. Scotto, M. Dauca, and W. Wahli Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat Endocrinology 137 1996 354 366
8. G. Chinetti, S. Griglio, M. Antonucci, I.P. Torra, P. Delerive, and Z. Majd Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages J. Biol. Chem. 273 1998 25573 25580
9. G. Chinetti, J.C. Fruchart, and B. Staels Peroxisome proliferator- activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation Inflamm. Res. 49 2000 497 505
10. R.B. Clark, D. Bishop-Bailey, T. Estrada-Hernandez, T. Hla, L. Puddington, and S.J. Padula The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses J. Immunol. 164 2000 1364 1371
11. C. Faveeuw, S. Fougeray, V. Angeli, J. Fontaine, G. Chinetti, and P. Gosset Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells FEBS Lett. 486 2000 261 266
12. P. Gosset, A.S. Charbonnier, P. Delerive, J. Fontaine, B. Staels, and J. Pestel Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells Eur. J. Immunol. 31 2001 2857 2865
13. N. Marx, G. Sukhova, C. Murphy, P. Libby, and J. Plutzky Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro Am. J. Pathol. 153 1998 17 23
14. X.Y. Yang, L.H. Wang, T. Chen, D.R. Hodge, J.H. Resau, and L. DaSilva Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT J. Biol. Chem. 275 2000 4541 4544
15. M. Gurnell PPARgamma and metabolism: insights from the study of human genetic variants Clin. Endocrinol. (Oxf) 59 2003 267 277
16. L. Dubuquoy, S. Dharancy, S. Nutten, S. Pettersson, J. Auwerx, and P. Desreumaux Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases Lancet 360 2002 1410 1418
17. Y. Kodera, K. Takeyama, A. Murayama, M. Suzawa, Y. Masuhiro, and S. Kato Ligand type-specific interactions of peroxisome proliferator-activated receptor gamma with transcriptional coactivators J. Biol. Chem. 275 2000 33201 33204
18. M. Li, G. Pascual, and C.K. Glass Peroxisome proliferator-activated receptor gamma-dependent repression of the inducible nitric oxide synthase gene Mol. Cell Biol. 20 2000 4699 4707
19. S.W. Chung, B.Y. Kang, S.H. Kim, Y.K. Pak, D. Cho, and G. Trinchieri Oxidized low density lipoprotein inhibits interleukin-12 production in lipopolysaccharide-activated mouse macrophages via direct interactions between peroxisome proliferator-activated receptor-gamma and nuclear factor-kappa B J. Biol. Chem. 275 2000 32681 32687
20. P. Desreumaux, L. Dubuquoy, S. Nutten, M. Peuchmaur, W. Englaro, and K. Schoonjans Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies J. Exp. Med. 193 2001 827 838
21. T.M. Willson, P.J. Brown, D.D. Sternbach, and B.R. Henke The PPARs: from orphan receptors to drug discovery J. Med. Chem. 43 2000 527 550
22. B.M. Forman, P. Tontonoz, J. Chen, R.P. Brun, B.M. Spiegelman, and R.M. Evans 15-deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma Cell 83 1995 803 812
23. F.A. Fitzpatrick, and M.A. Wynalda Albumin-catalyzed metabolism of prostaglandin D2. Identification of products formed in vitro J. Biol. Chem. 258 1983 11713 11718
24. S.A. Kliewer, J.M. Lenhard, T.M. Willson, I. Patel, D.C. Morris, and J.M. Lehmann A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation Cell 83 1995 813 819
25. W.S. Powell 15-deoxy-delta12,14-PGJ2: endogenous PPARgamma ligand or minor eicosanoid degradation product? J. Clin. Invest. 112 2003 828 830
26. L.C. Bell-Parikh, T. Ide, J.A. Lawson, P. McNamara, M. Reilly, and G.A. FitzGerald Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma J. Clin. Invest. 112 2003 945 955
27. A. Chawla, Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R.M. Evans PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation Nat. Med. 7 2001 48 52
28. A. Rossi, P. Kapahi, G. Natoli, T. Takahashi, Y. Chen, and M. Karin Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase Nature 403 2000 103 108
29. D.S. Straus, G. Pascual, M. Li, J.S. Welch, M. Ricote, and C.H. Hsiang 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway Proc. Natl. Acad. Sci. U. S. A 97 2000 4844 4849
30. J. Berger, P. Bailey, C. Biswas, C.A. Cullinan, T.W. Doebber, and N.S. Hayes Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice Endocrinology 137 1996 4189 4195
31. H. Hauner The mode of action of thiazolidinediones Diabetes Metab. Res. Rev. 18 Suppl. 2 2002 S10 S15
32. Y. Miyazaki, L. Glass, C. Triplitt, M. Matsuda, K. Cusi, and A. Mahankali Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients Diabetologia 44 2001 2210 2219
33. Y. Miyazaki, A. Mahankali, M. Matsuda, L. Glass, S. Mahankali, and E. Ferrannini Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone Diabetes Care 24 2001 710 719
34. Y. Miyazaki, A. Mahankali, M. Matsuda, S. Mahankali, J. Hardies, and K. Cusi Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J. Clin. Endocrinol. Metab. 87 2002 2784 2791
35. J.J. Nolan, B. Ludvik, P. Beerdsen, M. Joyce, and J. Olefsky Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone N. Engl. J. Med. 331 1994 1188 1193
36. Y. Miyazaki, M. Matsuda, and R.A. DeFronzo Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes Diabetes Care 25 2002 517 523
37. H. Yki-Jarvinen Thiazolidinediones N. Engl. J. Med. 351 2004 1106 1118
38. A. von Knethen, and B. Brune PPARgamma-an important regulator of monocyte/macrophage function Arch. Immunol. Ther. Exp. (Warsz.) 51 2003 219 226
39. M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, and C.K. Glass The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation Nature 391 1998 79 82
40. M. Ricote, J. Huang, L. Fajas, A. Li, J. Welch, and J. Najib Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein Proc. Natl. Acad. Sci. U. S. A 95 1998 7614 7619
41. P. Tontonoz, L. Nagy, J.G. Alvarez, V.A. Thomazy, and R.M. Evans PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL Cell 93 1998 241 252
42. C. Jiang, A.T. Ting, and B. Seed PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines Nature 391 1998 82 86
43. P.R. Colville-Nash, S.S. Qureshi, D. Willis, and D.A. Willoughby Inhibition of inducible nitric oxide synthase by peroxisome proliferator- activated receptor agonists: correlation with induction of heme oxygenase 1 J. Immunol. 161 1998 978 984
44. P. Gong, D. Stewart, B. Hu, N. Li, J. Cook, and A. Nel Activation of the mouse heme oxygenase-1 gene by 15-deoxy-delta(12,14)-prostaglandin J(2) is mediated by the stress response elements and transcription factor Nrf2 Antioxid. Redox Signal. 4 2002 249 257
45. J.T. Huang, J.S. Welch, M. Ricote, C.J. Binder, T.M. Willson, and C. Kelly Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase Nature 400 1999 378 382
46. Y. Azuma, M. Shinohara, P.L. Wang, and K. Ohura 15-deoxy-delta(12,14)- prostaglandin J(2) inhibits IL-10 and IL-12 production by macrophages Biochem. Biophys. Res. Commun. 283 2001 344 346
47. H. Inoue, T. Tanabe, and K. Umesono Feedback control of cyclooxygenase-2 expression through PPARgamma J. Biol. Chem. 275 2000 28028 28032
48. L.B. Maggi Jr., H. Sadeghi, C. Weigand, A.L. Scarim, M.R. Heitmeier, and J.A. Corbett Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression Diabetes 49 2000 346 355
49. M. Ishibashi, K. Egashira, K. Hiasa, S. Inoue, W. Ni, and Q. Zhao Antiinflammatory and antiarteriosclerotic effects of pioglitazone Hypertension 40 2002 687 693
50. Y. Takata, Y. Kitami, Z.H. Yang, M. Nakamura, T. Okura, and K. Hiwada Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma Circ. Res. 91 2002 427 433
51. S. Cuzzocrea, N.S. Wayman, E. Mazzon, L. Dugo, R. Di Paola, and I. Serraino The cyclopentenone prostaglandin 15-deoxy-delta(12,14)-prostaglandin J(2) attenuates the development of acute and chronic inflammation Mol. Pharmacol. 61 2002 997 1007
52. S. Cuzzocrea, E. Mazzon, L. Dugo, N.S. Patel, I. Serraino, and R. Di Paola Reduction in the evolution of murine type II collagen-induced arthritis by treatment with rosiglitazone, a ligand of the peroxisome proliferator-activated receptor gamma Arthritis Rheum. 48 2003 3544 3556
53. S. Cuzzocrea, B. Pisano, L. Dugo, A. Ianaro, P. Maffia, and N.S. Patel Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation Eur. J. Pharmacol. 483 2004 79 93
54. S. Cuzzocrea, B. Pisano, L. Dugo, A. Ianaro, D. Britti, and N.S. Patel Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute pancreatitis induced by cerulein Intensive Care Med. 30 2004 951 956
55. C.N. Ellis, J. Varani, G.J. Fisher, M.E. Zeigler, H.A. Pershadsingh, and S.C. Benson Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation Arch. Dermatol. 136 2000 609 616
56. N. Bhagavathula, K.C. Nerusu, A. Lal, C.N. Ellis, A. Chittiboyina, and M.A. Avery Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes J. Invest. Dermatol. 122 2004 130 139
57. M. Shimabukuro, S. Higa, T. Shinzato, F. Nagamine, I. Komiya, and N. Takasu Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats Metabolism 45 1996 1168 1173
58. N. Khandoudi, P. Delerive, I. Berrebi-Bertrand, R.E. Buckingham, B. Staels, and A. Bril Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury Diabetes 51 2002 1507 1514
59. P. Zhu, L. Lu, Y. Xu, and G.G. Schwartz Troglitazone improves recovery of left ventricular function after regional ischemia in pigs Circulation 101 2000 1165 1171
60. C. Thiemermann, and N.S. Wayman Menarini academy cardiovascular research awards in basic science 2001: ligands of the orphan receptor peroxisome-proliferator activator-gamma reduce myocardial infarct size Med. Sci. Monit. 7 2001 787 789
61. N.S. Wayman, Y. Hattori, M.C. McDonald, H. Mota-Filipe, S. Cuzzocrea, and B. Pisano Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size FASEB J. 16 2002 1027 1040
62. H. Ito, A. Nakano, M. Kinoshita, and A. Matsumori Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia/reperfusion injury in a rat model Lab. Invest. 83 2003 1715 1721
63. Tl.T.L. Yue, J. Chen, W. Bao, P.K. Narayanan, A. Bril, and W. Jiang In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone Circulation 104 2001 2588 2594
64. H.R. Liu, L. Tao, E. Gao, B.L. Lopez, T.A. Christopher, and R.N. Willette Anti-apoptotic effects of rosiglitazone in hypercholesterolemic rabbits subjected to myocardial ischemia and reperfusion Cardiovasc. Res. 62 2004 135 144
65. L. Tao, H.R. Liu, E. Gao, Z.P. Teng, B.L. Lopez, and T.A. Christopher Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia Circulation 108 2003 2805 2811
66. Y. Xu, M. Gen, L. Lu, J. Fox, S.O. Weiss, and R.D. Brown PPAR-{gamma} activation fails to provide myocardial protection in ischemia and reperfusion in pigs Am. J. Physiol., Heart Circ. Physiol. 2004 [Electronic publication print ahead]
67. A. Nakajima, K. Wada, H. Miki, N. Kubota, N. Nakajima, and Y. Terauchi Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury Gastroenterology 120 2001 460 469
68. Y. Naito, T. Takagi, K. Uchiyama, O. Handa, N. Tomatsuri, and E. Imamoto Suppression of intestinal ischemia-reperfusion injury by a specific peroxisome proliferator-activated receptor-gamma ligand, pioglitazone, in rats Redox. Rep. 7 2002 294 299
69. S. Cuzzocrea, B. Pisano, L. Dugo, A. Ianaro, N.S. Patel, and R. Di Paola Rosiglitazone and 15-deoxy-delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut Br. J. Pharmacol. 140 2003 366 376
70. H. Ichikawa, Y. Naito, T. Takagi, N. Tomatsuri, N. Yoshida, and T. Yoshikawa A specific peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand, pioglitazone, ameliorates gastric mucosal damage induced by ischemia and reperfusion in rats Redox. Rep. 7 2002 343 346
71. P.C. Konturek, T. Brzozowski, J. Kania, V. Kukharsky, K. Bazela, and S. Kwiecien Pioglitazone, a specific ligand of the peroxisome proliferator- activated receptor gamma reduces gastric mucosal injury induced by ischaemia/reperfusion in rat Scand. J. Gastroenterol. 38 2003 468 476
72. K. Wada, A. Nakajima, H. Takahashi, M. Yoneda, N. Fujisawa, and E. Ohsawa Protective effect of endogenous PPARgamma against acute gastric mucosal lesions associated with ischemia-reperfusion Am. J. Physiol., Gastrointest. Liver Physiol. 287 2004 G452 G458
73. A. Sivarajah, P.K. Chatterjee, N.S. Patel, Z. Todorovic, Y. Hattori, and P.A. Brown Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury Am. J. Nephrol. 23 2003 267 276
74. M. Okada, S.F. Yan, and D.J. Pinsky Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets FASEB J. 16 2002 1861 1868
75. K. Ito, J. Shimada, D. Kato, S. Toda, T. Takagi, and Y. Naito Protective effects of preischemic treatment with pioglitazone, a peroxisome proliferator-activated receptor-gamma ligand, on lung ischemia-reperfusion injury in rats Eur. J. Cardiothorac. Surg. 25 2004 530 536
76. K. Guyton, B. Zingarelli, S. Ashton, G. Teti, G. Tempel, and C. Reilly Peroxisome proliferator-activated receptor-gamma agonists modulate macrophage activation by Gram-negative and Gram-positive bacterial stimuli Shock 20 2003 56 62
77. M. Collin, and C. Thiemermann The PPAR-gamma ligand 15-deoxy(delta12,14) prostaglandin J2 reduces the liver injury in endotoxic shock Eur. J. Pharmacol. 476 2003 257 258
78. M. Collin, N.S. Patel, L. Dugo, and C. Thiemermann Role of peroxisome proliferator-activated receptor-gamma in the protection afforded by 15-deoxydelta12,14 prostaglandin J2 against the multiple organ failure caused by endotoxin Crit. Care Med. 32 2004 826 831
79. L. Dugo, M. Collin, S. Cuzzocrea, and C. Thiemermann 15d-prostaglandin J(2) reduces multiple organ failure caused by wall-fragment of Gram-positive and Gram-negative bacteria Eur. J. Pharmacol. 498 2004 295 301
80. S. Cuzzocrea, B. Pisano, L. Dugo, A. Ianaro, N.S. Patel, and R. Di Paola Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces the development of nonseptic shock induced by zymosan in mice Crit. Care Med. 32 2004 457 466
81. B. Zingarelli, M. Sheehan, P.W. Hake, M. O'Connor, A. Denenberg, and J.A. Cook Peroxisome proliferator activator receptor-gamma ligands, 15-deoxy-delta(12,14)-prostaglandin J2 and ciglitazone, reduce systemic inflammation in polymicrobial sepsis by modulation of signal transduction pathways J. Immunol. 171 2003 6827 6837
82. M. Abdelrahman, M. Collin, and C. Thiemermann The peroxisome proliferator-activated receptor-gamma ligand 15-deoxyD12,14 prostaglandin J2 reduces the organ injury in hemorrhagic shock Shock 22 2004 555 561
83. M. Collin, M. Abdelrahman, and C. Thiemermann Endogenous ligands of PPAR-gamma reduce the liver injury in haemorrhagic shock Eur. J. Pharmacol. 486 2004 233 235
84. Y. Naito, and T. Yoshikawa Thiazolidinediones: a new class of drugs for the therapy of ischemia-reperfusion injury Drugs Today (Barc.) 40 2004 423 430
85. H.A. Pershadsingh Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis? Expert Opin. Investig. Drugs 13 2004 215 228
86. S.M. Rangwala, and M.A. Lazar Peroxisome proliferator-activated receptor gamma in diabetes and metabolism Trends Pharmacol. Sci. 25 2004 331 336
87. T.L. Yue Cardioprotective effects of thiazolidinediones, peroxisome proliferator-activated receptor-gamma agonists Drugs Today (Barc.) 39 2003 949 960